Group items tagged

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

[350 Pages Report] Next Generation Sequencing (NGS) Market categories the global market by Platforms (MiSeq, Illumina HiSeq, 454 Roche, Life Technologies Ion Proton/PGM, by Bioinformatics (RNA-Seq, ChIP-Seq), (SBS, SMRT & Pyrosequencing,), (Diagnostics, Personalized Medicine) & by Geography

Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017

abortion harm next fetal

This research report categorizes and analyzes the global next generation sequencing market on the basis of steps in the NGS workflow and applications. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2012, 2013, and 2014 forecast to 2020. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

The global automated external defibrillator market was worth $616million in the year 2012. The market will grow at a healthy pace in the next five years due to the increasing incidence of cardiovascular disease, growing awareness about the lifesaving potential of AED